The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.
 
Francesca Bergamo
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; SERVIER
Speakers' Bureau - Bayer; Eisai; Lilly; MSD Oncology
 
Giada Munari
No Relationships to Disclose
 
Krisida Cerma
No Relationships to Disclose
 
Carlotta Ceccon
No Relationships to Disclose
 
Rossana Intini
No Relationships to Disclose
 
Chiara Borga
No Relationships to Disclose
 
Riccardo Cerantola
No Relationships to Disclose
 
Vittoria Matilde Piva
No Relationships to Disclose
 
Valentina Angerilli
No Relationships to Disclose
 
Alessandra Anna Anna Prete
No Relationships to Disclose
 
Aldo Montagna
No Relationships to Disclose
 
Mario Domenico Rizzato
No Relationships to Disclose
 
Marianna Sabbadin
No Relationships to Disclose
 
Giulia Barsotti
No Relationships to Disclose
 
Chiara De Toni
No Relationships to Disclose
 
Letizia Procaccio
No Relationships to Disclose
 
Caterina Soldà
No Relationships to Disclose
 
Angelo Paolo Dei Tos
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Lilly; Merck Serono; Mirati Therapeutics; MSD; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Matteo Fassan
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; GlaxoSmithKline; MSD Oncology; Pierre Fabre; Roche
Research Funding - Astellas Pharma; Diaceutics; Macrophage Pharma; QED Therapeutics